United Therapeutics Corp’s recently made public that its Director ROTHBLATT MARTINE A unloaded Company’s shares for reported $0.98 million on May 17 ’24. In the deal valued at $273.27 per share,3,600 shares were sold. As a result of this transaction, ROTHBLATT MARTINE A now holds 130 shares worth roughly $35774.7.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, ROTHBLATT MARTINE A sold 3,600 shares, generating $980,534 in total proceeds. Upon selling the shares at $272.37, the Director now owns 130 shares.
Before that, EDGEMOND JAMES sold 40,160 shares. United Therapeutics Corp shares valued at $10,951,230 were divested by the CFO AND TREASURER at a price of $272.69 per share. As a result of the transaction, EDGEMOND JAMES now holds 1,578 shares, worth roughly $0.43 million.
Goldman upgraded its United Therapeutics Corp [UTHR] rating to a Neutral from a a Sell in a research note published on February 12, 2024; the price target was increased to $215 from $213. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Wells Fargo began covering UTHR with “an Overweight” recommendation on December 08, 2023. UBS started covering the stock on December 06, 2022. It rated UTHR as “a Buy”.
Price Performance Review of UTHR
On Tuesday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock jump 0.19% to $275.19. Over the last five days, the stock has gained 2.01%. United Therapeutics Corp shares have risen nearly 25.15% since the year began. Nevertheless, the stocks have risen 25.34% over the past one year. While a 52-week high of $275.42 was reached on 05/21/24, a 52-week low of $204.44 was recorded on 02/08/24. SMA at 50 days reached $245.42, while 200 days put it at $231.66. A total of 0.32 million shares were traded, compared to the trading of 0.29 million shares in the previous session.
Levels Of Support And Resistance For UTHR Stock
The 24-hour chart illustrates a support level at 272.47, which if violated will result in even more drops to 269.74. On the upside, there is a resistance level at 278.95. A further resistance level may holdings at 282.70. The Relative Strength Index (RSI) on the 14-day chart is 73.06, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 7.43, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 18.39%. Stochastics %K at 92.63% indicates the stock is a selling.
The most recent change occurred on December 05, 2022 when Goldman began covering the stock and recommended ‘”a Sell”‘ rating along with a $230 price target.
